Acura and King receive letter

PALATINE - Acura Pharmaceuticals Inc. and King Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration issued a Complete Response Letter regarding the new drug application for Acurox Tablets CII, a product intended for the relief of moderate-to-severe pain. The letter raises issues regarding the potential abuse deterrent benefits of Acurox. Acura, with offices in Palatine, and King said that at this stage, say they believe they can respond to the issues raised without conducting any additional studies.